Beacon Therapeutics Trial Met Primary Endpoint
The Phase 2/3 VISTA trial data shows improved low-light vision in patients with X-linked retinitis pigmentosa.
Updated on Oct. 12, 2026 in Biotech
Live Poll
Should the government prioritize fast-track approval for new gene therapies targeting rare, incurable diseases?
Beacon Therapeutics presented results from the VISTA trial, which met its primary endpoint in patients with X-linked retinitis pigmentosa. The study found that a gene therapy, laru-zova, improved low luminance visual acuity compared to an untreated control group.
Why it matters
This development marks a milestone in evaluating gene therapy for X-linked retinitis pigmentosa, a condition that currently lacks effective treatments. The positive results support the progression of laru-zova toward a regulatory filing.
The VISTA trial tested laru-zova at doses of 6.8 E+11 vg/eye and 3.7 E+11 vg/eye. Results showed 31.0% of high-dose participants and 24.1% of low-dose participants achieved a 15-letter improvement in low luminance visual acuity (LLVA) at Month 12.
The players
Beacon Therapeutics
A biotechnology company focused on developing gene therapies to restore vision for patients with inherited retinal diseases.
The details
Participants received subretinal injections of laru-zova, a gene therapy designed to address the underlying genetic cause of X-linked retinitis pigmentosa. Researchers used low luminance visual acuity — a measure of vision in dim light — and microperimetry — a test to map the sensitivity of the retina — to evaluate progress. The study monitored safety, noting that laru-zova-related adverse events occurred in 25% of high-dose participants and 38% of those in the low-dose group.
Timeline
October 9-12, 2026: American Academy of Ophthalmology Annual Meeting held in New Orleans.
October 10, 2026: Results from the VISTA trial presented to researchers.
October 12, 2026: Formal data summary published for the trial.
The Tech Race
The VISTA trial provides a key benchmark for the development of ocular gene therapies. It establishes a quantitative performance target for competitors aiming to treat inherited retinal diseases using similar viral vector delivery platforms.
The findings are currently limited to clinical trial participants and do not impact patient care or clinical availability today. The therapy is intended for males aged 12 to 48 diagnosed with X-linked retinitis pigmentosa, pending future regulatory approval and commercial rollout.
The takeaway
The VISTA trial successfully demonstrated that subretinal laru-zova injections can improve visual acuity in patients with X-linked retinitis pigmentosa. Stakeholders should watch for the initiation of the rolling Biologics License Application submission expected in 2026.
What happens next
Beacon Therapeutics plans to initiate a rolling Biologics License Application submission for laru-zova in 2026.
Further reading
For broader trends in genetic medicine, see the latest developments in Biotech.
Live Poll
Should the government prioritize fast-track approval for new gene therapies targeting rare, incurable diseases?
